These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16824641)

  • 21. Public-Private Partnerships in the health sector: the Danish experience.
    Vrangbaek K
    Health Econ Policy Law; 2008 Apr; 3(Pt 2):141-63. PubMed ID: 18634625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biopharma business models in Canada.
    March-Chordà I; Yagüe-Perales RM
    Drug Discov Today; 2011 Aug; 16(15-16):654-8. PubMed ID: 21708279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing the socioeconomic determinants of adolescent health: experiences from the WHO/HBSC Forum 2007.
    Koller T; Morgan A; Guerreiro A; Currie C; Ziglio E;
    Int J Public Health; 2009 Sep; 54 Suppl 2():278-84. PubMed ID: 19639252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Industry and pharmaceutical research in Italy. How to make up for lost time].
    Mortari U
    Recenti Prog Med; 2006 Nov; 97(11):634-9. PubMed ID: 17252720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Government intervention and innovation in industry: a policy framework.
    Abernathy WJ; Chakravarthy BS
    Sloan Manage Rev; 1979; ():3-18. PubMed ID: 10248178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating research into action: a case study on trans fatty acid research and nutrition policy in Costa Rica.
    Colón-Ramos U; Lindsay AC; Monge-Rojas R; Greaney ML; Campos H; Peterson KE
    Health Policy Plan; 2007 Nov; 22(6):363-74. PubMed ID: 17951318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manage customer-centric innovation--systematically.
    Selden L; MacMillan IC
    Harv Bus Rev; 2006 Apr; 84(4):108-16; 149. PubMed ID: 16579418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in public and private sector adoption of telemedicine: Indian case study for sectoral adoption.
    Sood SP; Negash S; Mbarika VW; Kifle M; Prakash N
    Stud Health Technol Inform; 2007; 130():257-68. PubMed ID: 17917199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of computing technology on pharmaceutical and biotech research.
    Owen J
    IDrugs; 2005 Oct; 8(10):834-7. PubMed ID: 16254804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
    Garattini L; Motterlini N; Cornago D
    Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Swiss Startup Framework: A Highly Effective Network Supporting the Generation of Emerging Biotech Businesses.
    Mitchell I; Steiner S; Altorfer M; Suter-Dick L
    Chimia (Aarau); 2020 Oct; 74(10):765-767. PubMed ID: 33115556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of China's medical biotech industry needs to be driven by innovation.
    Yu Z; Dai Y
    Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Building capacity of environmental health services at the local and national levels with the 10-essential-services framework.
    George LS; Fulop M; Wickham L
    J Environ Health; 2007; 70(1):17-20, 63. PubMed ID: 17802811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based policy-making: the implications of globally-applicable research for context-specific problem-solving in developing countries.
    Behague D; Tawiah C; Rosato M; Some T; Morrison J
    Soc Sci Med; 2009 Nov; 69(10):1539-46. PubMed ID: 19781839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.